Physician profile
Brenda E Lapierre
NPI 1831940444
$1,574.20
in general payments reported to CMS, 2019-2025
12 companies · $961 in 2025
The $961 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $613 · 2025: $961.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,574.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,574.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $407.90 | 2024-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $400.13 | 2024-2025 | |
| Novo Nordisk INC | $235.37 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Otsuka America Pharmaceutical, INC. | $103.38 | 2024-2025 | Rexulti, Abilify Maintena |
| Vanda Pharmaceuticals INC. | $99.98 | 2024-2025 | Fanapt |
| Amgen INC. | $93.18 | 2025 | Repatha, Otezla |
| Exact Sciences Corporation | $60.79 | 2024-2025 | Cologuard Collection Kit |
| Pfizer INC. | $51.36 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $49.89 | 2024-2025 | Ajovy, Austedo Xr |
| Astellas Pharma US INC | $36.60 | 2024-2025 | Veozah |
| Organon LLC | $21.02 | 2025 | Nexplanon |
| Glaxosmithkline, LLC. | $14.60 | 2025 | Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brenda Lapierre listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.